Get all premium features to the best stock analysis tool

LOS ANGELES, March 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Disc Medicine, Inc. (“Disc Medicine" or the "Company") (NASDAQ: IRON) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

WATERTOWN, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that the last participant has been randomized and dosed in the pivotal Phase 3 APOLLO trial of bitopertin in EPP. Originally planned as an N=150 study, the study was expanded to 183 participants due to patient and physician demand.

New York, New York--(Newsfile Corp. - March 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Investigation examines gap between reported figures and GAAP results at Disc Medicine ahead of its 21.9% stock collapse NEW YORK, March 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating whether Disc Medicine, Inc. (NASDAQ: IRON) and certain of its officers fulfilled their disclosure obligations to investors in the period leading up to the company's announcement of a Complete Response Letter from the FDA. Shareholders who purchased IRON shares and incurred losses may obtain further information by contacting Levi & Korsinsky.

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. (“Disc” or the “Company”) (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.